Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
167.47
+1.91 (1.15%)
At close: Oct 9, 2026, 4:00 PM EDT
169.64
+2.17 (1.30%)
After-hours: Oct 9, 2026, 7:57 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $334.98M in the quarter ending June 30, 2026, with 44.33% growth. This brings the company's revenue in the last twelve months to $1.18B, up 42.74% year-over-year. In the year 2025, Guardant Health had annual revenue of $982.02M with 32.88% growth. That makes Guardant Health the 6,867th largest company in the world by revenue and 1,680th in the United States.
Revenue (ttm)
$1.18B
Revenue Growth
+42.74%
P/S Ratio
19.00
Revenue / Employee
$472,109
Employees
2,506
Market Cap
22.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 982.02M | 243.01M | 32.88% |
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
| Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
| Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
| Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
| Dec 31, 2016 | 25.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.98B |
| Labcorp Holdings | 14.35B |
| Quest Diagnostics | 11.56B |
| ICON Public Limited Company | 8.29B |
| Waters | 4.64B |
| IDEXX Laboratories | 4.55B |
| Illumina | 4.49B |
| Mettler-Toledo International | 4.13B |
GH News
- 1 day ago - Guardant Health price target raised to $200 from $195 at BofA - TheFly
- 1 day ago - Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion - TheFly
- 1 day ago - Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer - Business Wire
- 1 day ago - Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 - Business Wire
- 3 days ago - Guardant Health price target raised to $220 from $200 at Barclays - TheFly
- 4 days ago - Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250 - FXEmpire
- 4 days ago - Guardant Health reports COSMOS study published in Cancer Research Communications - TheFly
- 4 days ago - Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma - Business Wire